– USA, TX – AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced the appointments of Tom Finn and Dr. John Shiver (Ph.D.) to its Board of Directors.
“I am delighted to welcome Tom and John to the Board. They join AuraVax at an exciting time as our lead product, NanoSTING-001, advances to clinical testing. Their combined R&D, business development and commercial experience will be invaluable to guide the company’s growth,” said Board Chair, Laurence Cooper.
About Thomas Finn
Tom Finn is retired President of Procter & Gamble Global Health Care with three decades of experience in the pharmaceutical drug industry. He brings a wealth of knowledge on the commercial development of new products and an understanding of the varied customer segments. Before this role, Tom Finn held executive management roles at P&G, including President of Global Personal Health Care & Global Pharmaceuticals, VP of NA Pharmaceuticals, Global Strategic Planning, and New Business Development, VP of Worldwide Strategic Planning and New Business Development, and GM of Pharmaceuticals. Finn serves as a Board member of Cincinnati Children’s Medical Center and is Chair of their Research Committee. He also serves as a Board member for Eikonoklastes Therapeutics, a Biotech company developing gene therapy for amyotrophic lateral sclerosis. Finn received his BA in Economics from Hamilton College.
About Dr. John Shiver
Dr. John Shiver has three decades of experience in vaccine research and development at Sanofi Pasteur and Merck & Co., Inc. He helped develop vaccines and antibodies to prevent and treat more than 40 infectious and non-infectious and contributed to the licensure of 14 products. Shiver is CSO, and leader of the scientific advisory board of IGM ID, a subsidiary of IGM Biosciences. Shiver also serves as a board member of Icosavax Inc. and IAVI. Before IGM ID, he was the Global Head of Vaccines R&D and a member of the Executive Leadership team at Sanofi Pasteur. Shiver also serves as a board member of Icosavax Inc. and IAVI Boards of Directors. Before Sanofi, Shiver led vaccine research at Merck and served in the experimental immunology branch of the National Institutes of Health. Shiver is a fellow of the American Academy of Microbiology and the International Society for Vaccines. He is the author of over 150 articles in top-tier journals and is a co-author of 68 awarded patents.
About AuraVax
AuraVax Therapeutics, Inc. is a privately held biotechnology company commercializing a new platform termed “NanoSTING” to activate STING for the treatment and prevention of respiratory infections independent of the infecting virus. NanoSTING is a broad-acting, host-directed intranasal immune-antiviral to safely target the STING pathway and restore innate immunity for the prevention and treatment of respiratory disease and disrupt host-to-host transmission.
For more information: https://www.auravax.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
